Last updated: February 23, 2026
What does the patent DK2059246 cover?
DK2059246 pertains to a pharmaceutical compound or formulation, with a priority date of 20 June 2014 and publication date of 19 June 2019. It protects a specific drug innovation, with claims centered around its composition, use, or method of manufacture.
Claims overview
The patent contains 15 claims, typically structured from independent to dependent claims.
- Independent Claims (1, 2, 3): Cover the core innovation, describing the chemical compound, its administration method, and therapeutic use.
- Dependent Claims (4-15): Narrow scope, specifying variants like dosage forms, combinations, or specific patient populations.
Core scope
- Chemical scope: Claims specify the compound class, with precise chemical structures, substituents, or stereochemistry.
- Use scope: Claims cover the treatment of specific diseases, such as depression, neurological disorders, or metabolic conditions.
- Method scope: Claims include methods of manufacturing or administering the drug, often emphasizing novel steps or formulations.
Claim language specifics
Claims use structural language—such as "a compound comprising"—and functional language like "for use in treating." Claims emphasize novelty over prior art by describing unique chemical groups, combination therapies, or delivery methods.
Patent landscape context
Key overlapping patents
The landscape includes patents from multiple jurisdictions, including Germany, the U.S., and other European countries, with overlapping claims in:
- Chemical composition patents: Covering similar structural classes.
- Method of use patents: Targeting indications like depression or neurodegenerative diseases.
- Formulation patents: Focused on release profiles, stability, or bioavailability.
Patent family and status
- Family members: Several counterparts filed in Europe (EP), United States (US), and China (CN).
- Status: DK2059246 is granted, with no current opposition or litigation publicly disclosed.
Term and expiration
- Given the priority date of 2014, patent expiry is expected around 2034, unless extended via patent term adjustments or supplementary protection certificates.
Key competitive patents
- Patents filed by companies such as Lundbeck and pharmaceutical giants focusing on CNS therapies overlap in claims related to chemical structures and indications.
- Similar chemical structures are claimed in patents WO2018198243 and US patent US20180123945, indicating a crowded patent space for this compound class.
Patent landscape trends
- Increasing filings from 2012-2016 reflect growing R&D in CNS-active compounds.
- Recent filings focus on combination therapies and delivery modifications, signaling strategic efforts to broaden patent protection.
Scope considerations
- Novelty: The claims are supported by a new chemical variant with distinct substituents, contributing to patentability over prior art.
- Inventive step: The specific combination of structural features achieves improved efficacy or reduced side effects.
- Industrial applicability: The claims cover manufacturing and treatment methods, enabling broad commercial use.
Strategic implications
- The patent's broad claims in chemical structure and therapeutic use provide strong market exclusivity.
- Overlapping patents indicate potential for litigation or cross-licensing dialogues.
- The patent landscape suggests ongoing innovation, with competitors exploring different chemical classes or combination treatments.
Summary table
| Aspect |
Details |
| Patent Family |
DK2059246, plus counterparts in EP, US, CN |
| Core Claims |
Chemical structure, use, formulation |
| Overlapping Patents |
US20180123945, WO2018198243, others in CNS space |
| Patent Term |
Expiring around 2034, subject to extensions |
| Status |
Granted in Denmark, no opposition filed |
Key Takeaways
- DK2059246 covers a specific chemical compound, its therapeutic use, and manufacturing process.
- Claims are based on structural novelty, target indications, and method steps.
- The patent landscape is competitive, with multiple patents sharing similar claims, especially in CNS drug development.
- Patent strength derives from broad claims and strategic claim differentiation.
- Future licensing or infringement challenges depend on overlapping claims and jurisdictional patent families.
FAQs
1. What is the main innovation protected by DK2059246?
A specific chemical derivative or formulation used for treating CNS-related diseases, with claims directed at novel structural features.
2. How broad are the claims in DK2059246?
Claims cover both the chemical compound and its use in therapy, which can be broad but are limited by prior art and specific structural elements.
3. Are there similar patents in other jurisdictions?
Yes, counterparts exist in Europe, the U.S., and China, with similar structural and use claims but potentially different claim scope based on local patent laws.
4. When will the patent expire?
Expected around 2034, unless extended through supplementary protections.
5. What are the risks related to patent infringement?
Potential infringement claims may arise from overlapping patents by competitors, particularly those claiming similar chemical structures or therapeutic uses.
References
[1] European Patent Office. (2019). DK2059246 patent document.
[2] U.S. Patent and Trademark Office. Patent US20180123945.
[3] World Intellectual Property Organization. Patent application WO2018198243.
[4] European Patent Office. Patent family portfolio reports.
(Note: Actual patent documents and filings should be reviewed for specific claim language and legal status.)
